Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 392542, 5 pages
http://dx.doi.org/10.1155/2011/392542
Review Article

PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

University of Michigan Scleroderma Program, Ann Arbor, MI 48106-5753, USA

Received 2 June 2011; Accepted 2 August 2011

Academic Editor: Eswar Krishnan

Copyright © 2011 Ann J. Impens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Lin, G. Lin, Z. C. Xin, and T. F. Lue, “Expression, distribution and regulation of phosphodiesterase 5,” Current Pharmaceutical Design, vol. 12, no. 27, pp. 3439–3457, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Wallis, J. D. Corbin, S. H. Francis, and P. Ellis, “Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro,” The American Journal of Cardiology, vol. 4, pp. 3C–12C, 1999. View at Google Scholar · View at Scopus
  3. B. Zhu, L. Zhang, M. Alexeyev, D. F. Alvarez, S. J. Strada, and T. Stevens, “Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 296, no. 2, pp. L220–L228, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. P. J. Wright, “Comparison of phosphodiesterase type 5 (PDE5) inhibitors,” International Journal of Clinical Practice, vol. 60, no. 8, pp. 967–975, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. N. Galiè, H. A. Ghofrani, A. Torbicki et al., “Sildenafil citrate therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. Galiè, B. H. Brundage, H. A. Ghofrani et al., “Tadalafil therapy for pulmonary arterial hypertension,” Circulation, vol. 119, no. 22, pp. 2894–2903, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Z. Jing, Z. Yu, J. Shen et al., “Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 12, pp. 1723–1729, 2011. View at Publisher · View at Google Scholar · View at PubMed
  8. F. Wigley, “Clinical practice. Raynaud's Phenomenon,” The New England Journal of Medicine, vol. 347, pp. 1001–1008, 2002. View at Google Scholar
  9. E. Schiopu, A. J. Impens, and K. Phillips, “Digital ischemia in scleroderma spectrum of diseases,” International Journal of Rheumatology, vol. 2010, Article ID 923743, 8 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. G. Jackson, “Vardenafil—PDE5 inhibitor number 3,” International Journal of Clinical Practice, vol. 58, no. 3, p. 229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Gore and R. Silver, “Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 64, no. 9, p. 1387, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. N. Kumar, B. Griffiths, and J. Allen, “Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment,” The Journal of Rheumatology, vol. 33, no. 9, pp. 1918–1919, 2006. View at Google Scholar · View at Scopus
  13. H. Watanabe, S. Nishio, E. Ohmae et al., “Sildenafil improves forearm blood flow in patients with Raynauds phenomenon,” The European Heart Journal, vol. 25 (supplement), p. 202, 2004. View at Google Scholar
  14. R. Fries, K. Shariat, H. von Wilmowsky, and M. Böhm, “Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy,” Circulation, vol. 112, no. 19, pp. 2980–2985, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. C. S. Brueckner, M. O. Becker, T. Kroencke et al., “Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study,” Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1475–1478, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. E. Caglayan, M. Huntgeburth, T. Karasch et al., “Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease,” Archives of Internal Medicine, vol. 166, no. 2, pp. 231–233, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. Baak, “Treatment of Raynaud's phenomena with the PDE-5 inhibitor, Cialis (tadalafil) in patients with scleroderma and lupus,” Arthritis and Rheumatism, vol. 52, p. S169, 2005. View at Google Scholar
  18. E. A. Friedman, P. A. Harris, A. J. Wood, C. M. Stein, and D. Kurnik, “The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon,” Clinical Pharmacology & Therapeutics, vol. 81, no. 4, pp. 503–509, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. G. Carlino, “Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor (abstract),” Annals of the Rheumatic Diseases, vol. 64, p. 258, 2005. View at Google Scholar
  20. E. Rosato, C. Letizia, M. Proietti et al., “Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis,” Journal of Biological Regulators and Homeostatic Agents, vol. 23, no. 1, pp. 23–29, 2009. View at Google Scholar · View at Scopus
  21. E. Schiopu, V. M. Hsu, A. J. Impens et al., “Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis,” The Journal of Rheumatology, vol. 36, no. 10, pp. 2264–2268, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. P. D. Shenoy, S. Kumar, L. K. Jha et al., “Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial,” Rheumatology, vol. 49, no. 12, pp. 2420–2428, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. V. Agarwal, P. Ghosh, A. Sharma et al., “Efficacy of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicenter study,” Arthritis and Rheumatism, vol. 62 (supplement), p. S872, 2010. View at Google Scholar